Review Article

Role of MALAT1 as a Prognostic Factor for Survival in Various Cancers: A Systematic Review of the Literature with Meta-Analysis

Yao Wei¹ and Ben Niu²

¹Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
²Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Correspondence should be addressed to Ben Niu; niubenniuben@gmail.com

Received 13 June 2015; Revised 22 August 2015; Accepted 24 August 2015

Objectives. The expression of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a highly abundant and ubiquitously expressed long noncoding RNA (lncRNA), influences clinical parameters and may have prognostic value in cancer. This meta-analysis evaluated the prognostic role of MALAT1 in various cancers.

Materials and Methods. Systematic literature searches of PubMed and EMBASE databases were conducted for eligible studies of the prognostic role of MALAT1 in cancer. Overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were analyzed. Summary hazard ratios (HRs) and 95% confidence intervals (95% CIs) were assessed to evaluate the influence of MALAT1 expression on patient prognosis.

Results. Nine studies with a total of 932 patients were included in the analysis. Elevated MALAT1 expression was significantly correlated with poor OS (HR 2.02; 95% CI: 1.62–2.52; \( P < 0.001 \); \( I^2 = 0\% \)). Subgroup analysis indicated that tumor type, histology type, ethnicity, and measurement technique did not affect the prognostic value of MALAT1 for OS. The HR of elevated MALAT1 for DFS was 2.78 (95% CI: 1.87–4.15; \( P < 0.001 \); \( I^2 = 0\% \)). Conclusions. Elevated MALAT1 expression is correlated with poor OS in various types of cancer, suggesting that this gene is a prognostic factor for different types of cancer.

1. Introduction

Noncoding RNAs (ncRNAs) are RNAs that do not encode proteins and play important roles [1, 2]. Small ncRNAs, such as microRNAs (miRNAs), have been extensively studied in association with many human diseases [3]. However, long noncoding RNAs (lncRNAs), which are commonly defined as RNA molecules with lengths of greater than 200 nucleotides, have a broad range of molecular and cellular functions via distinct mechanisms that are not yet fully understood [4]. Accumulating reports of aberrant lncRNA expression in various cancers indicate that lncRNAs may substantially contribute to cancer development [5].

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also named nuclear-enriched abundant transcript 2 (NEAT2), is a widely expressed lncRNA that is greater than 8000 nucleotides in length. MALAT1 was first identified as a factor indicating high metastatic potential and poor prognosis in a study of gene expression differences in stage I non-small-cell lung cancer (NSCLC) with/without metastasis [6]. MALAT1 has since been associated with several human neoplasms, including lung [7, 8], liver [9], renal [10], colorectal [11], gastric [12], breast [13], cervical [14], pancreatic [15], and bladder cancers [16], uterine endometrial stromal sarcoma [17], glioma [18], and osteosarcoma [19]. The expression of this gene may affect the clinical parameters and prognosis of cancer patients. However, most studies assessing the implications of MALAT1 expression in cancer have been limited by small sample sizes and have produced controversial results. Therefore, we performed a systematic review and quantitative meta-analysis to assess the prognostic role of MALAT1 expression in various cancers.
2. Materials and Methods

2.1. Literature Search Strategy. Electronic searches of PubMed and EMBASE were performed using the following keywords: “MALAT1,” “MALAT-1,” “MALAT1 long non-coding RNA, human,” “metastasis-associated lung adenocarcinoma transcript 1,” “NEAT2,” “NEAT2 long non-coding RNA, human,” “carcinoma,” “neoplasm,” “cancer,” “prognosis,” “prognostic,” and “outcome,” without any limits. The reference lists of the retrieved articles were searched manually. The search ended in February 2015.

2.2. Eligibility Criteria. The eligibility criteria for the studies were as follows: (1) evaluation of a link between MALAT1 expression and prognosis of patients with any type of cancer; (2) reporting of outcomes, including overall survival (OS), disease-specific survival (DSS), or disease-free survival (DFS); (3) reporting of hazard ratios (HRs) and 95% confidence intervals (CIs) or data that could be used to calculate these values; and (4) full papers in English. Nonhuman research, duplicated studies, reviews, letters, comments, and single case reports were omitted.

2.3. Data Extraction. Yao Wei and Ben Niu reviewed each eligible study and extracted the data. The following information was collected: author; year of publication; country; cancer type and stage; number of patients; techniques used to assess MALAT1 expression; follow-up period; and cut-off values, HRs, and corresponding 95% CIs for OS, DSS, or DFS. HRs were directly determined by multivariate analysis in some studies, whereas others provided Kaplan-Meier survival curves. For the latter studies, we first extracted several specific points from the survival curves using Engauge Digitizer version 4.1 to obtain two lists of survival rates at specific time points from the two survival curves. We then input the extracted survival rates at specific time points into the spreadsheet developed by Tierney et al. to calculate the HR and 95% CI [20]. Finally, we produced an approximated curve and compared it with the original curves to confirm the accuracy of our data extraction.

2.4. Quality Assessment. Yao Wei and Ben Niu performed a quality assessment of the included studies according to the guidelines of Hayden et al. [21]. This assessment included evaluations of the following six items: study participation, study attrition, prognostic factor measurements, confounding measurements and relevant adjustments, outcome measurements, and analysis. The results for each item were described as "yes," "no," "partly," or "unsure." Consensus was achieved after each item was discussed, and the overall risk was determined for each potential bias.

2.5. Statistical Analysis. We evaluated the impact of MALAT1 expression on clinical prognosis by examining the HRs and corresponding 95% CIs. An observed HR of >1 indicated poorer prognosis in patients with elevated MALAT1 expression. The results were considered statistically significant when the 95% CI did not overlap with 1. We used I² statistic to assess statistical heterogeneity between studies. Significant heterogeneity was defined as I² > 50%. If there was no significant heterogeneity between studies, the fixed-effects model was used. Otherwise, the random-effects model was used. Subgroup analysis with stratification by tumor type, histology type, ethnicity, and measurement method was conducted. Sensitivity analysis was performed with sequential omission of each study. Probable publication bias was estimated by Begg’s test and by constructing a funnel plot. All P values were two tailed, and P < 0.05 was considered statistically significant. Review Manager version 5.3 and STATA software version 11.0 (Stata Corporation, College Station, Texas, USA) were used to conduct statistical analysis.

3. Results

3.1. Included Studies and Characteristics. A flow diagram of the literature search process is presented in Figure 1. Sixty-six papers were obtained by PubMed and EMBASE searches. Forty-six articles were excluded after the abstracts were reviewed. Additional 11 articles were excluded after the full papers were assessed. Ultimately, 9 articles were included in this meta-analysis.

The clinical characteristics of the 9 included studies are summarized in Table 1. The articles were published between 2011 and 2015 with sample sizes ranging from 45 to 150 and included a total of 932 participants. Six of the studies enrolled more than 100 participants each. The participants in the studies were from China, Germany, and Japan. Seven different types of cancer were examined (2 studies of NSCLC, 2 of pancreatic cancer, 1 of clear cell renal cell carcinoma, 1 of gastric cancer, 1 of colorectal cancer, 1 of hepatocellular carcinoma, and 1 of glioma). HRs and 95% CIs were directly retrieved from 8 studies and were calculated from survival curves for 1 study.

The results of the quality assessment are presented in Table 2. The key baseline characteristics of the study sample were not adequately described in Shen LQ’s study. Further, the key characteristics of participants lost to follow-up were not described in Schmidt LH’s study. In addition, Lai MC’s study did not include a well-defined cut-off MALAT1 expression level. The duration of follow-up was not clearly described in 3 studies (those of Zhang HM, Schmidt LH, and Shen LQ). None of the studies described important confounders, such as subsequent treatments.

3.2. Primary Outcome: OS. The main results of the meta-analysis are presented in Table 3. Seven studies including 793 participants reported HRs for OS or DSS. HRs and 95% CIs were directly determined by multivariate analysis in all 7 studies. Elevated MALAT1 expression was predictive of poor OS (HR 2.02; 95% CI: 1.62–2.52; P < 0.001; Figure 2). The fixed-effects model was used because of evidence of nonsignificant heterogeneity (P = 0.452, I² = 0%) among the studies. The effects of elevated MALAT1 expression on OS among different tumor types, histology types, and ethnicities and according to different measurement methods are presented in Table 3 and Figure 3.
Records identified through database searching PubMed ($n = 33$) Additional records identified through EMBASE ($n = 63$) Records after duplicates removed ($n = 66$) Records screened ($n = 66$) Full-text articles assessed for eligibility ($n = 20$) Studies included in qualitative synthesis ($n = 9$) Studies included in quantitative synthesis (meta-analysis) ($n = 9$) HR for overall survival ($n = 6$) HR for disease-free survival ($n = 3$) HR for disease-specific survival ($n = 1$)

The change of MALAT1 was evaluated ($n = 1$) The correlation of the expression of MALAT1 with response to chemotherapy was evaluated ($n = 1$) No data about HRs or no adequate data to be calculated ($n = 5$) Review ($n = 1$) Duplicate published articles ($n = 3$)

Figure 1: Flow diagram of the meta-analysis.

| Study or subgroup | Log[hazard ratio] | SE     | Weight | Hazard ratio IV, fixed, 95% CI | Hazard ratio IV, fixed, 95% CI |
|-------------------|-------------------|--------|--------|------------------------------|------------------------------|
| Pang et al., 2014 | 0.5658818         | 0.239475 | 21.8%  | 1.76 [1.10, 2.82]             |                              |
| Zhang et al., 2014| 1.126876          | 0.345534 | 10.5%  | 3.09 [1.57, 6.07]             |                              |
| Zheng et al., 2014| 1.378262          | 0.443068 | 6.4%   | 3.97 [1.67, 9.46]             |                              |
| Schmidt et al., 2011| 0.5766134      | 0.25373 | 19.4%  | 1.78 [1.08, 2.93]             |                              |
| Okugawa et al., 2014 | 0.4317824     | 0.263054 | 18.1%  | 1.54 [0.92, 2.58]             |                              |
| Ma et al., 2015    | 0.8272409         | 0.260752 | 18.4%  | 2.29 [1.37, 3.81]             |                              |
| Liu et al., 2014   | 0.5866749         | 0.480698 | 5.4%   | 1.80 [0.70, 4.61]             |                              |
| Total (95% CI)     |                   |        | 100.0% | 2.02 [1.62, 2.52]             |                              |

Heterogeneity: $\chi^2 = 5.75$, df = 6 ($P = 0.45$); $I^2 = 0\%$
Test for overall effect: $Z = 6.29$ ($P < 0.00001$)

Figure 2: Forest plots of the HRs of elevated MALAT1 expression for overall survival for the included studies. Log[hazard ratio]: logarithm of the hazard ratio; SE: standard error; weight: the weight given to each study by the inverse of the variance of the hazard ratio. IV: inverse variance; fixed: fixed-effects analysis.
Table 1: Characteristics of the studies included in the meta-analysis.

| First author | Year | Country | Cancer type | Stage | Sample size ($n$) | Method | Cut-off | Follow-up (months) | Outcome | Survival analysis |
|--------------|------|---------|-------------|-------|-------------------|--------|---------|-------------------|---------|------------------|
| Pang [15]    | 2015 | China   | Pancreatic cancer | I–IV  | 126               | RT-qPCR | Median value of 6.23 | 5–60    | OS                |
| Zhang [10]   | 2014 | China   | Renal cell carcinoma (clear cell) | I–IV  | 106               | RT-qPCR | Mean value of 3.85 | NA      | OS                |
| Liu [29]     | 2014 | China   | Pancreatic duct adenocarcinoma | I–IV  | 45                | RT-qPCR | Mean value (NA)     | 24–36   | DSS               |
| Zheng [11]   | 2014 | China   | Colorectal cancer | II–III| 146               | RT-qPCR | 6.15 (MALAT1/GAPDH ratio) | 11–72.8 | DFS, OS           |
| Schmidt [7]  | 2011 | Germany | Non-small-cell lung cancer (squamous cell) | I–III | 102               | ISH    | A large gene copy cluster in 50% of cells | NA      | OS                |
| Okugawa [12] | 2014 | Japan   | Gastric cancer | I–IV  | 150               | RT-qPCR | Threshold of 0.985  | 1–78    | OS                |
| Shen [8]     | 2014 | China   | Non-small-cell lung cancer | NA    | 79                | RT-qPCR | Mean value (NA)    | NA      | DFS               |
| Lai [9]      | 2012 | China   | Hepatocellular carcinoma | NA    | 60                | RT-qPCR | NA                 | 18.6 (median) | DFS               |
| Ma [18]      | 2015 | China   | Glioma      | I–IV  | 118               | RT-qPCR | Median value of 5.18 | 5 years | OS                |

RT-qPCR: real-time quantitative PCR; ISH: in situ hybridization; OS: overall survival; DFS: disease-free survival; DSS: disease-specific survival; NA: not available.

Table 2: Quality assessment of the studies included in the meta-analysis.

| First author | Study participation | Study attrition | Prognostic factor measurement | Outcome measurement | Confounding measurements and adjustments | Analysis |
|--------------|---------------------|-----------------|-------------------------------|---------------------|------------------------------------------|----------|
| Pang [15]    | Yes                 | Yes             | Yes                           | Yes                 | Partly                                   | Yes      |
| Zhang [10]   | Yes                 | Yes             | Yes                           | Yes                 | Partly                                   | Yes      |
| Liu [29]     | Yes                 | Yes             | Yes                           | Yes                 | Partly                                   | Yes      |
| Zheng [11]   | Yes                 | Yes             | Yes                           | Yes                 | Partly                                   | Yes      |
| Schmidt [7]  | Yes                 | Partly          | Yes                           | Yes                 | Partly                                   | Yes      |
| Okugawa [12] | Yes                 | Yes             | Partly                        | Yes                 | Partly                                   | Yes      |
| Shen [8]     | Partly              | Yes             | Yes                           | Yes                 | Partly                                   | Yes      |
| Lai [9]      | Yes                 | Partly          | Yes                           | Yes                 | Partly                                   | Yes      |
| Ma [18]      | Yes                 | Yes             | Yes                           | Yes                 | Partly                                   | Yes      |

Sensitivity analysis indicated that the pooled HR was not significantly affected by the exclusion of any of the studies (Figure 4).

The funnel plot indicated no significant asymmetry (Figure 5). $P$ value of Egger's regression intercepts was 0.170. Therefore, no significant publication bias was detected in this meta-analysis.

3.3. Secondary Outcome: DFS. Three studies including 285 participants reported HRs for DFS (Table 3). The HRs and
### Disease Markers

| Study or subgroup | Log(hazard ratio) | SE     | Weight | Hazard ratio IV, fixed, 95% CI | Hazard ratio IV, fixed, 95% CI |
|------------------|------------------|--------|--------|-------------------------------|-------------------------------|
| **1.1 Digestive system** |                  |        |        |                               |                               |
| Liu et al., 2014  | 0.5866749        | 0.4806981 | 10.5%  | 1.80 [0.70, 4.61]             |                               |
| Okugawa et al., 2014 | 0.4317824       | 0.263054 | 35.0%  | 1.54 [0.92, 2.58]             |                               |
| Pang et al., 2014  | 0.3658818        | 0.2394754 | 42.2%  | 1.76 [1.10, 2.82]             |                               |
| Zheng et al., 2014 | 1.378262         | 0.443068 | 12.3%  | 3.97 [1.67, 9.46]             |                               |
| **Subtotal (95% CI)** | **100.0%**       | **1.86 [1.37, 2.35]** |        |                               |                               |
| Heterogeneity: $\chi^2 = 3.50$, df = 3 ($P = 0.32$); $I^2 = 14\%$ | Test for overall effect: $Z = 3.99$ ($P < 0.0001$) | | | | |

1.2 Nondigestive system

| Study or subgroup | Log(hazard ratio) | SE     | Weight | Hazard ratio IV, fixed, 95% CI | Hazard ratio IV, fixed, 95% CI |
|------------------|------------------|--------|--------|-------------------------------|-------------------------------|
| Ma et al., 2015  | 0.8272409        | 0.260752 | 38.1%  | 2.29 [1.37, 3.81]             |                               |
| Schmidt et al., 2011 | 0.5766134       | 0.253737 | 40.2%  | 1.78 [1.08, 2.93]             |                               |
| Zhang et al., 2014 | 1.126876         | 0.345534 | 21.7%  | 3.09 [1.57, 6.07]             |                               |
| **Subtotal (95% CI)** | **100.0%**       | **2.21 [1.61, 3.02]** |        |                               |                               |
| Heterogeneity: $\chi^2 = 1.68$, df = 2 ($P = 0.43$); $I^2 = 0\%$ | Test for overall effect: $Z = 4.92$ ($P < 0.00001$) | | | | |

1.3 Squamous carcinoma

| Study or subgroup | Log(hazard ratio) | SE     | Weight | Hazard ratio IV, fixed, 95% CI | Hazard ratio IV, fixed, 95% CI |
|------------------|------------------|--------|--------|-------------------------------|-------------------------------|
| Liu et al., 2014  | 0.5866749        | 0.4806981 | 8.7%  | 1.80 [0.70, 4.61]             |                               |
| Okugawa et al., 2014 | 0.4317824       | 0.263054 | 29.1%  | 1.54 [0.92, 2.58]             |                               |
| Pang et al., 2014  | 0.5658818        | 0.2394754 | 35.1%  | 1.76 [1.10, 2.82]             |                               |
| Zheng et al., 2014 | 1.126876         | 0.345534 | 16.9%  | 3.09 [1.57, 6.07]             |                               |
| Zheng et al., 2014 | 1.378262         | 0.443068 | 10.3%  | 3.97 [1.67, 9.46]             |                               |
| **Subtotal (95% CI)** | **100.0%**       | **2.03 [1.53, 2.68]** |        |                               |                               |
| Heterogeneity: $\chi^2 = 5.28$, df = 4 ($P = 0.26$); $I^2 = 24\%$ | Test for overall effect: $Z = 4.98$ ($P < 0.00001$) | | | | |

1.2 Others

| Study or subgroup | Log(hazard ratio) | SE     | Weight | Hazard ratio IV, fixed, 95% CI | Hazard ratio IV, fixed, 95% CI |
|------------------|------------------|--------|--------|-------------------------------|-------------------------------|
| Ma et al., 2015  | 0.8272409        | 0.2607517 | 100.0% | 2.29 [1.37, 3.81]             |                               |
| **Subtotal (95% CI)** | **100.0%**       | **2.29 [1.37, 3.81]** |        |                               |                               |
| Heterogeneity: not applicable | Test for overall effect: $Z = 3.17$ ($P = 0.002$) | | | | |

Figure 3: Continued.
### Table 3: The main results of the pooled analyses.

| Survival | Variables       | Number of studies | Number of patients | HR   | 95% CI           | P value | Heterogeneity (I², %) |
|----------|-----------------|-------------------|--------------------|------|------------------|---------|-----------------------|
| OS       | All             | 7                 | 793                | 2.02 | 1.62–2.52        | <0.001  | 0                     |
| Tumor type | Digestive system | 4                 | 467                | 1.86 | 1.37–2.53        | <0.001  | 14.2                  |
| Tumor type | Nondigestive system | 3                | 326                | 2.21 | 1.61–3.02        | <0.001  | 0                     |
| Histology type | Adenocarcinoma | 5                 | 573                | 2.03 | 1.53–2.68        | <0.001  | 24.2                  |
| Histology type | Squamous carcinoma | 1              | 102                | 1.78 | 1.08–2.92        |         |                       |
| Histology type | Others         | 1                 | 118                | 2.29 | 1.37–3.81        |         |                       |
| Ethnicity | Asian           | 6                 | 691                | 2.08 | 1.63–2.66        | <0.001  | 8.1                   |
| Ethnicity | Caucasian       | 1                 | 102                | 1.78 | 1.08–2.92        |         |                       |
| Method   | RT-qPCR         | 6                 | 691                | 2.08 | 1.63–2.66        | <0.001  | 8.1                   |
| Method   | ISH             | 1                 | 102                | 1.78 | 1.08–2.92        |         |                       |
| DFS      | All             | 3                 | 285                | 2.78 | 1.87–4.15        | <0.001  | 0                     |

RT-qPCR: real-time quantitative PCR; ISH: in situ hybridization; OS: overall survival; DFS: disease-free survival.

95% CIs were determined by multivariate analysis in 2 studies and calculated from the survival curve in 1 study. Elevated MALAT1 expression was predictive of decreased DFS (HR 2.78; 95% CI: 1.87–4.15; P < 0.001; Figure 6). The fixed-effects model was used because of evidence of nonsignificant heterogeneity (P = 0.848, I² = 0.0%) among the studies.

### 4. Discussion

The prognostic role of MALAT1 in cancer was evaluated by a meta-analysis of 9 studies including 932 participants. Elevated MALAT1 expression was indicative of poor prognosis in patients with various types of cancer. The pooled HR for OS was 2.02 (95% CI: 1.62–2.52; P < 0.001), and the...
HRs were similar among the different tumor types, histology types, races, and measurement methods. There was evidence of nonsignificant heterogeneity ($P = 0.452, I^2 = 0\%$) among the studies. Sensitivity analysis demonstrated that the pooled HR was not significantly affected by the exclusion of any of the studies. No publication bias was detected. Elevated MALAT1 expression was associated with poorer DFS, although the role of MALAT1 in cancer development requires further evaluation.

The mechanism underlying the relationship between elevated MALAT1 expression and poor prognosis in patients with various types of cancer is uncertain. MALAT1 may regulate alternative splicing. MALAT1 interacts with serine/arginine proteins and influences the distribution of splicing factors in nuclear speckle domains [22]. In MALAT1-depleted cells, the expression of an oncogenic transcription factor, B-MYB (Mybl2), which is involved in G2/M progression, is reduced because of the aberrant binding of splicing factors and abnormal alternative splicing [23]. However, its capacity for regulating alternative splicing could not be confirmed in MALAT1 knockout mice or lung cancer cells [24, 25]. MALAT1 has critical and specific functions in regulating the expression of several target genes. Depletion of MALAT1 from HeLa cells represses the expression of several genes, including ZF-5'-oligoadenylate synthetase-like protein, interferon-induced protein 44, and serine peptidase inhibitor Kazal type 4 [26]. In lung cancer, MALAT1 regulates a series of metastasis-associated genes, and thus the migratory ability of MALAT1-deficient cells is impaired [24]. MALAT1 is also involved in the transcriptional control of cell cycle gene expression and is required for the recruitment of coactivators by polycomb 2 (Pc2) to the promoters of cell cycle control genes [27]. Decreases in the levels of epithelial-mesenchymal transition- (EMT-) associated ZEB1, ZEB2, and Slug and an increase in that of E-cadherin occur upon downregulation of MALAT1 [16].

The elucidation of prognostic factors is crucial for the identification of high-risk patients who are good candidates for individual therapy. The results of our meta-analysis indicate that elevated MALAT1 expression affects the prognosis of cancer patients, and these findings should promote the development of adequately designed prospective studies. Furthermore, this gene might represent a potential therapeutic target. MALAT1 knockdown strategies may be developed for antimetastatic therapy. Studies of the function of MALAT1 in the vasculature have revealed that its inhibition induces a switch from an endothelial cell phenotype to a promigratory but antiproliferative state, resulting in impaired endothelial cell proliferation in vitro and in vivo and reduced retinal vessel growth [28]. MALAT1 inhibition may elicit an antiangiogenic effect in the hypoxic tumor environment.

There are several limitations of our study. First, the pooled survival data were calculated based on results reported for patients with various types of cancer because the available studies were heterogeneous. The prognostic role of MALAT1 in each type of cancer could not be evaluated because of the limited data available. Second, there was a bias towards Asian patients because 7 of 9 studies were from China and one study was from Japan. Third, the techniques used to identify MALAT1 expression could have led to possible bias. In most of the studies, MALAT1 expression was detected by real-time quantitative PCR, except in Schmidt LH’s study, which employed in situ hybridization. However, in situ hybridization is far less sensitive and quantitative than real-time quantitative PCR. Moreover, cut-off values were not reported in some studies, and those that were reported were inconsistent among studies, which may have reduced the power for detecting a real association. Fourth, most of the included studies reported significant results because studies with nonsignificant results may not be published. Moreover, some authors described significant results of subgroup analyses but did not report the results for other nonsignificant subgroups. Fifth, subsequent treatment after surgery differed among the studies and can greatly influence survival, leading to some heterogeneity. Sixth, OS was the endpoint in a majority of the studies, except for Liu JH’s study, which used DSS as the endpoint. This study was also included in analysis of the pooled HR for OS, which may not have been
In conclusion, MALAT1 may be a prognostic factor for patients with various types of cancer. Further studies are needed to confirm its precise role among other known prognostic factors for specific types of cancer.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**References**

1. R. Spizzo, M. I. Almeida, A. Colombatti, and G. A. Calin, "Long non-coding RNAs and cancer: a new frontier of translational research," *Oncogene*, vol. 31, no. 43, pp. 4577–4587, 2012.
2. K. C. Wang and H. Y. Chang, "Molecular mechanisms of long noncoding RNAs," *Molecular Cell*, vol. 43, no. 6, pp. 904–914, 2011.
3. I. Berindan-Neagoe, P. D. C. Monroig, B. Pasculli, and G. A. Calin, "MicroRNAome: a genome for cancer diagnosis and therapy," *CA: Cancer Journal for Clinicians*, vol. 64, no. 5, pp. 311–336, 2014.
4. J. E. Wilusz, H. Sunwoo, and D. L. Spector, "Long noncoding RNAs: functional surprises from the RNA world," *Genes and Development*, vol. 23, no. 13, pp. 1494–1504, 2009.
5. T. Gutschner and S. Diederichs, "The hallmarks of cancer: a long non-coding RNA point of view," *RNA Biology*, vol. 9, no. 6, pp. 703–709, 2012.
6. P. Ji, S. Diederichs, W. Wang et al., "MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer," *Oncogene*, vol. 22, no. 39, pp. 8031–8041, 2003.
7. L. H. Schmidt, T. Spieker, S. Koschmieder et al., "The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces tumor growth," *Journal of Thoracic Oncology*, vol. 6, no. 12, pp. 1984–1992, 2011.
8. L. Shen, L. Chen, Y. Wang, X. Jiang, H. Xia, and Z. Zhuang, "Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer," *Journal of Neuro-Oncology*, vol. 121, no. 1, pp. 101–108, 2014.
9. M.-C. Lai, Z. Yang, L. Zhou et al., "Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation," *Medical Oncology*, vol. 29, no. 3, pp. 1810–1816, 2012.
10. H.-M. Zhang, F.-Q. Yang, S.-J. Chen, J. Che, and J.-H. Zheng, "Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma," *Tumor Biology*, vol. 36, no. 4, pp. 2947–2955, 2014.
11. H.-T. Zheng, D.-B. Shi, Y.-W. Wang et al., "High expression of IncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer," *International Journal of Clinical and Experimental Pathology*, vol. 7, no. 6, pp. 3174–3181, 2014.
12. Y. Okugawa, Y. Toiyama, K. Hur et al., "Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis," *Carcinogenesis*, vol. 35, no. 12, pp. 2731–2739, 2014.
13. M. J. Ellis, L. Ding, D. Shen et al., "Whole-genome analysis informs breast cancer response to aromatase inhibition," *Nature*, vol. 486, no. 7403, pp. 353–360, 2012.
14. F. Guo, Y. Li, Y. Liu, J. Wang, Y. Li, and G. Li, "Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion," *Acta Biochimica et Biophysica Sinica*, vol. 42, no. 3, pp. 224–229, 2010.
15. E.-J. Pang, R. Yang, X.-B. Fu, and Y.-F. Liu, "Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer," *Tumor Biology*, vol. 36, no. 4, pp. 2403–2407, 2015.
16. L. Ying, Q. Chen, Y. Wang, Z. Zhou, Y. Huang, and F. Qiu, "Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition," *Molecular BioSystems*, vol. 8, no. 9, pp. 2289–2294, 2012.
17. K. Yamada, J. Kano, H. Tsunoda et al., "Phenotypic characterization of endometrial stromal sarcoma of the uterus," *Cancer Science*, vol. 97, no. 2, pp. 106–112, 2006.
18. K.-X. Ma, H.-J. Wang, X.-R. Li et al., "Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma," *Tumor Biology*, 2015.
19. J. Fellenberg, L. Bernd, G. Delling, D. Witte, and A. Zahlen-Hingurapan, "Prognostic significance of drug-regulated genes in high-grade osteosarcoma," *Modern Pathology*, vol. 20, no. 10, pp. 1085–1094, 2007.
20. J. F. Tierney, L. A. Stewart, D. Gherzi, S. Burdett, and M. R. Sydes, "Practical methods for incorporating summary time-to-event data into meta-analysis," *Trials*, vol. 8, article 16, 2007.
[21] J. A. Hayden, P. Côté, and C. Bombardier, “Evaluation of the quality of prognosis studies in systematic reviews,” *Annals of Internal Medicine*, vol. 144, no. 6, pp. 427–437, 2006.

[22] V. Tripathi, J. D. Ellis, Z. Shen et al., “The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation,” *Molecular Cell*, vol. 39, no. 6, pp. 925–938, 2010.

[23] V. Tripathi, Z. Shen, A. Chakraborty et al., “Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB,” *PLoS Genetics*, vol. 9, no. 3, Article ID e1003368, 2013.

[24] T. Gutschner, M. Hämmerle, M. Eißmann et al., “The non-coding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells,” *Cancer Research*, vol. 73, no. 3, pp. 1180–1189, 2013.

[25] B. Zhang, G. Arun, Y. S. Mao et al., “The IncRNA malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult,” *Cell Reports*, vol. 2, no. 1, pp. 111–123, 2012.

[26] R. Miyagawa, K. Tano, R. I. E. Mizuno et al., “Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles,” *RNA*, vol. 18, no. 4, pp. 738–751, 2012.

[27] L. Yang, C. Lin, W. Liu et al., “ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs,” *Cell*, vol. 147, no. 4, pp. 773–788, 2011.

[28] K. M. Michalik, X. You, Y. Manavski et al., “Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth,” *Circulation Research*, vol. 114, no. 9, pp. 1389–1397, 2014.

[29] J.-H. Liu, G. Chen, Y.-W. Dang, C.-J. Li, and D.-Z. Luo, “Expression and prognostic significance of IncRNA MALAT1 in pancreatic cancer tissues,” *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 7, pp. 2971–2977, 2014.